Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | -66.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.25 | N/A | -66.67% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the EPS miss.
The earnings report indicates that Xenon Pharmaceutical is still navigating challenges, as evidenced by the EPS miss. However, the stock rose by 5.52%, likely due to investor optimism about the company's ongoing clinical programs. The lack of guidance may create uncertainty for investors looking for direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE MGMT INC DEL
Nov 2, 2020